ByettaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11

542 records returned

A Comparison of Costs among Patients with Type 2 Diabetes Mellitus Who Initiated Therapy with Exenatide or Insulin GlargineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - November 14, 2009 Category: Health Management Authors: Misurski, DerekLage, Maureen J.Fabunmi, RosalindBoye, Kristina S. Tags: Original Research Articles Source Type: journals

Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Much recent attention has focused on the GLP-1 receptor as a potential target for antidiabetic drugs. Enzyme resistant GLP-1 mimetics such as exenatide are now employed for the treatment of type 2 diabetes, but must be administered by injection. The present study has examined and compared the in vitro and in vivo metabolic actions of a small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB), with native GLP-1, exenatide and liraglutide. DMB significantly stimulated in vitro insulin secretion from BRIN BD11 cells but with decreased molar potency compared to native GLP-1 o...
Source: European Journal of Pharmacology - November 13, 2009 Category: Drugs & Pharmacology Authors: Irwin N, Flatt PR, Patterson S, Green BD Tags: Eur J Pharmacol Source Type: journals

Byetta (Exenatide Injection) - updated on RxListEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Byetta (Exenatide Injection) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 12, 2009 Category: Drugs & Pharmacology Source Type: consumer

Byetta label changed to include renal failure warningsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 11, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exerciseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions/interpretation In non-diabetic participants given exenatide, blood glucose concentrations rise rather than fall during aerobic exercise with an associated greater catecholamine response. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00125-009-1579-1Authors E. Y. H. Khoo, Nottingham University Hospitals Department of Diabetes and Endocrinology Queens Medical Centre Campus, Derby Road Nottingham NG7 2UH UKJ. Wallis, University of Nottingham School of Biomedical Sciences Nottingham UKK. Tsintzas, University of Nottingham School of Biomedical Sciences Nottingham UKI. A. M...
Source: Diabetologia - November 7, 2009 Category: Endocrinology Tags: Diabetologia Source Type: journals

Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ITCA 650 induces potent reductions of HbA1c and body weight after 4 week treatment; ITCA 650 delivers up to 12 months of exenatide therapy from a single DUROS device HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 6, 2009 Category: Pharmaceuticals Source Type: clinical trials

FDA to revise prescribing information for exenatide, sitagliptinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration has approved drug label revisions for the GLP-1 agonist exenatide to incorporate information obtained from post-marketing reports of acute renal failure and insufficiency experienced by some patients taking the drug. (Source: MedWire News - Diabetes)
Source: MedWire News - Diabetes - November 6, 2009 Category: Endocrinology Source Type: news

FDA Approves Revisions to Prescribing Information for Diabetes MedicationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has approved revisions to the prescribing information for the injectable diabetes medication exenatide and the diabetes drug sitagliptin phosphate because of concerns about, respectively, renal problems and pancreatitis caused by the medications. (Source: AAFP Clinical Care and Research)
Source: AAFP Clinical Care and Research - November 4, 2009 Category: Primary Care Source Type: news

FDA Working to Revise Prescribing Information for Diabetes MedicationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA is revising the prescribing information for the injectable diabetes medication exenatide and the oral diabetes drug sitagliptin phosphate following reports of renal problems associated with exenatide use, as well as reports linking sitagliptin use with pancreatitis. (Source: AAFP Clinical Care and Research)
Source: AAFP Clinical Care and Research - November 4, 2009 Category: Primary Care Source Type: news

FDA: Diabetes drug Byetta tied to kidney problemsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
People with type 2 diabetes who are taking the blood-sugar-lowering drug Byetta may be at increased risk for kidney problems, including kidney failure, the U.S. Food and Drug Administration reported this week. (Source: CNN.com - Health)
Source: CNN.com - Health - November 4, 2009 Category: Consumer Health News Source Type: news

Health News of the DayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day:FDA Issues Warning for Diabetes Drug Byetta about possible kidney problems, including renal failure http://bit.ly/1UOjwB"Who are the sleepiest people in the US?" Source: Morbidity and Mortality Weekly Report http://bit.ly/4djMWPX-rays showed 78 different items of cutlery in a 52-year-old woman's stomach http://bit.ly/4iojkQMayo Clinic: 10 great health foods for eating well http://bit.ly/sGLgF"Hospitals with hospitalists have...
Source: Clinical Cases and Images - November 4, 2009 Category: Journals (General) Tags: Health News of the Day Source Type: info

FDA expands exenatide use; warns of renal-failure riskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has issued a warning about exenatide the same day the agency approved its first-line use along with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. (Source: theHeart.org)
Source: theHeart.org - November 3, 2009 Category: Cardiology Source Type: info

FDA Approves Exenatide for First-Line Use; Warns of Renal Failure RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has issued a warning about exenatide the same day the agency approved its first-line use along with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 3, 2009 Category: Consumer Health News Tags: Diabetes & Endocrinology Source Type: news

FDA Issues Warning for Diabetes DrugEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Reports of kidney problems for those using Byetta prompted action Source: HealthDay Related MedlinePlus Topics: Diabetes Medicines, Drug Safety (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 3, 2009 Category: Consumer Health News Source Type: consumer

Exenatide Label Updated to Highlight Kidney RisksEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 3, 2009 Category: Primary Care Tags: Medical News Source Type: info

Amylin Pharmaceuticals And Eli Lilly And Company Statement On FDA's BYETTA(R) (Exenatide) Injection UpdateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection. "The FDA update issued today aligns with the BYETTA label approved last week. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 3, 2009 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

FDA approves exenatide (Byetta®) as monotherapy for type 2 diabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: BioSpace Area: News According to BioSpace, the FDA has approved an additional indication for exenatide (Byetta®), as monotherapy along with diet and exercise to improve glycaemic control in adults with type 2 diabetes. Previously, it was approved for use only in patients who were also taking metformin and/or sulphonylureas and had not achieved adequate glycaemic control on maximal doses of these therapies [it is currently licensed for this indication only in the UK]. The approval of this additional indication was based on a clinical study which found that patients with type 2 diabetes who were unable t...
Source: NeLM - News - November 3, 2009 Category: Drugs & Pharmacology Source Type: organizations

US label of exenatide (Byetta®) revised to include post-marketing reports of altered kidney functionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: FDA Area: News The US FDA has notified healthcare professionals of revisions to the prescribing information for exenatide (Byetta®) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency. Exenatide is approved in the US as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. A total of 78 reports of altered kidney function (62 cases of acute renal failure and 16 cases of renal insufficiency) in patients receiving treatment with exenatide have been received by the FDA between Apri...
Source: NeLM - News - November 3, 2009 Category: Drugs & Pharmacology Source Type: organizations

FDA Warns Exenatide Could Cause Kidney ProblemsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The U.S. Food and Drug Administration has revised the label of the type 2 diabetes drug exenatide (Byetta) to provide information about possible kidney function problems, including kidney failure, according to a Nov. 2 press release issued by the agency. (Source: Modern Medicine)
Source: Modern Medicine - November 3, 2009 Category: Journals (General) Source Type: info

Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's Byetta (Exenatide) Injection UpdateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN DIEGO and INDIANAPOLIS, Nov. 2, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (NASDAQ:AMLN) and Eli Lilly and Company (NYSE:LLY) today issued the following statement in response to the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 2, 2009 Category: Pharmaceuticals Source Type: news

Byetta (exenatide) - Altered kidney function, including acute renal failure/renal insufficiency, in patients on ByettaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ROCKVILLE, Md., Nov. 2, 2009--FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 2, 2009 Category: Pharmaceuticals Source Type: news

Byetta (exenatide) - Renal FailureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cases of altered kidney function, including acute renal failure and renal insufficiency, in patients using Byetta. (Source: FDA MedWatch)
Source: FDA MedWatch - November 2, 2009 Category: American Health Source Type: organizations

FDA: Byetta Label Revised to Include Safety Information on Possible Kidney ProblemsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 2, 2009 Category: American Health Source Type: organizations

FDA Okays Diabetes Drug for First-Line Use, Adds WarningEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
WASHINGTON (MedPage Today) -- The FDA expanded the indication and prescribing language for the type 2 diabetes drug exenatide (Byetta). (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 2, 2009 Category: Cardiology Source Type: news

Byetta Approved for Expanded Use as First-Line Treatment for Type 2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Byetta (exenatide)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 2, 2009 Category: Drugs & Pharmacology Source Type: news

FDA: Byetta Label Revised To Include Safety Information On Possible Kidney ProblemsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - November 2, 2009 Category: Pharmaceuticals Source Type: news

Byetta (exenatide) - Renal FailureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Audience: Endocrine and nephrology healthcare professionals FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function,... (Source: Drugs.com - FDA MedWatch Alerts)
Source: Drugs.com - FDA MedWatch Alerts - November 2, 2009 Category: Drugs & Pharmacology Source Type: news

FDA gives Byetta nod as stand-alone diabetes treatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has approved an expanded indication for Amylin Pharmaceuticals and Eli Lilly’s Byetta (exenatide) injection for use as a stand-alone medication (monotherapy) along with diet and exercise, to improve glycemic control in adults with type 2 diabetes. (Source: Cardiovascular Business News)
Source: Cardiovascular Business News - November 1, 2009 Category: Cardiology Tags: Latest News Source Type: news

FDA approves Byetta as stand-alone diabetes treatment, with caveatsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has approved an expanded indication for Amylin Pharmaceuticals and Eli Lilly’s Byetta (exenatide) injection for use as a stand-alone medication (monotherapy) along with diet and exercise, to improve glycemic control in adults with type 2 diabetes. (Source: Cardiovascular Business News)
Source: Cardiovascular Business News - November 1, 2009 Category: Cardiology Tags: Latest News Source Type: news

Exenatide: Acute pancreatitis: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 31, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

BYETTA Approved For Expanded Use As First-Line Treatment For Type 2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 31, 2009 Category: Consumer Health News Tags: Diabetes Source Type: news

Phase III study of once weekly GLP-1 analogue taspoglutide vs. exenatide meets primary endpointEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: BioSpace Area: News Ipsen and Roche have announced the results of the first phase III clinical study using taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue. The T-EMERGE 2 study is an open-label, 24-week non-inferiority study involving 1189 patients, randomised into three active arms (subcutaneous weekly taspoglutide 10mg or 20mg, and subcutaneous twice-daily exenatide 10mcg, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD). All patients continue into long-term extension of the study, The study demonstrated superiority versus exenatide in HbA1c reduction ...
Source: NeLM - News - October 30, 2009 Category: Drugs & Pharmacology Source Type: organizations

First Phase III clinical trial of Roche's weekly taspoglutide meets primary end-point of change in HbA1cEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD), showed that the trial met its primary endpoint of change in HbA1c. Superiority versus exenatide was demonstrated. (Source: Roche Investor Update)
Source: Roche Investor Update - October 29, 2009 Category: Pharmaceuticals Source Type: organizations

First Phase III clinical trial of Roche`s weekly taspoglutide meets primary end-point of change in HbA1cEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD), showed that the trial met its primary endpoint of change in HbA1c. Superiority versus exenatide was demonstrated. (Source: Roche Investor Update)
Source: Roche Investor Update - October 29, 2009 Category: Pharmaceuticals Source Type: organizations

New Study Results Show That Patients Have Higher Treatment Satisfaction With Liraglutide Compared to ExenatideEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
MONTREAL, Oct. 22 /CNW/ - New data on patient treatment satisfaction from the LEAD(TM) 6 trial presented on the 22nd October at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 24, 2009 Category: Pharmaceuticals Source Type: clinical trials

Weekly exenatide demonstrates QOL superiority in T2DMEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 19, 2009 Category: Health Management Tags: Research article Source Type: journals

Exenatide and sitagliptin appear to carry no higher risk of acute pancreatitis than metformin or glibenclamide [glyburide]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 12, 2009 Category: Drugs & Pharmacology Tags: Research article Source Type: journals

Albiglutide is effective and well tolerated for treatment of Type 2 diabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The long-acting glucagon-like peptide-1 receptor agonist albiglutide can reduce glycated hemoglobin levels as effectively as exenatide in patients with inadequately controlled Type 2 diabetes, report researchers. (Source: MedWire News - Diabetes)
Source: MedWire News - Diabetes - October 10, 2009 Category: Endocrinology Source Type: news

Effects of Exenatide Alone and in Combination with Daclizumab on Beta Cell Function in Long-Standing Type 1 Diabetes Mellitus.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions - In long-standing type 1 diabetes, which remains an active autoimmune disease even decades after its onset, surviving beta-cells secrete insulin in a physiologically regulated manner. However, the combination of intensified insulin therapy, exenatide, and daclizumab did not induce improved function of these remaining beta-cells. PMID: 19808924 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - October 5, 2009 Category: Endocrinology Authors: Rother KI, Spain LM, Wesley RA, Digon BJ, Baron A, Chen K, Nelson P, Dosch HM, Palmer J, Brooks-Worrell B, Ring M, Harlan DM Tags: Diabetes Care Source Type: journals

Merck Blockbuster Diabetes Drug: Januvia Linked to PancreatitisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(NaturalNews) U.S. health officials said on Friday they suspect Merck`s blockbuster diabetes drug Januvia to be linked to pancreatitis, a potentially fatal condition marked by serious inflammation of the pancreas. As might be expected, Merck company officials disputed the connection.According to the Food and Drug Administration, 88 cases of acute pancreatitis had been reported since the drug`s approval in 2006 through February of this year by users of the drug and a related product Janumet, including two cases of hemorrhagic or necrotizing pancreatitis. The agency "believes there may be an association" with the drug, since...
Source: NaturalNews.com - October 5, 2009 Category: Consumer Health Advice Source Type: news

Use of exenatide does not increase risk for acute pancreatitisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Treatment of Type 2 diabetics with the glucagon-like peptide 1 analogue exenatide does not significantly increase the risk for acute pancreatitis compared with other antidiabetic drugs, report researchers. (Source: MedWire News - Diabetes)
Source: MedWire News - Diabetes - October 2, 2009 Category: Endocrinology Source Type: news

[Correspondence] Adverse events in diabetes drug trialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The LEAD-6 trial (July 4, p 39) presents safety data less transparently than efficacy data. The rate of serious adverse events with liraglutide was twice that with exenatide, but confidence intervals and p values are omitted, by contrast with the efficacy outcomes. The definition of serious adverse events included mortality and hospital admissions, but neither is described. These data should be supplied. (Source: LANCET)
Source: LANCET - October 1, 2009 Category: Journals (General) Authors: Christoph Pechlaner Tags: Correspondence Source Type: journals

[Correspondence] Adverse events in diabetes drug trial – Authors' replyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Christoph Pechlaner raises concerns that there were no statistical comparisons for the incidence of serious adverse events (liraglutide 12/235 [5·1%]; exenatide 6/232 [2·6%]). The study was not powered to investigate differences between treatment groups in terms of adverse events. We have, however, done a post-hoc analysis to address the concern over serious adverse events. An odds ratio was calculated by use of a cumulative logit model with severity levels (severe, moderate, mild, none) as ordinal categorical response variables. There was no significant difference between the serious adverse events for liraglutide and e...
Source: LANCET - October 1, 2009 Category: Journals (General) Authors: John B Buse, Ali Falahati Tags: Correspondence Source Type: journals

EASD: No Extra Risk of Acute Pancreatitis Seen with Exenatide (CME/CE)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
VIENNA (MedPage Today) -- Acute pancreatitis was not more common with exenatide (Byetta) use compared with other drugs for type 2 diabetes, researchers said here. (Source: MedPage Today Product Alert)
Source: MedPage Today Product Alert - October 1, 2009 Category: Drugs & Pharmacology Source Type: news

Study: Exenatide Aids Weight Loss in Nondiabetic PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
WASHINGTON — Exenatide helps increase weight loss in obese nondiabetic patients who also are following a diet and exercise program, study results suggest. Dr. Michael Trautmann, a researcher at Eli Lilly & Co., and his colleagues conducted a double-blind, placebo-controlled study of 152 patients with a mean body mass index of 39.6 kg/m2. The patients' average age was 46 years, and 82% were women. The average hemoglobin A1c was 5.5%. One-quarter of the patients had impaired glucose tolerance, and average blood pressure was 120/76 mm Hg. (Source: Ob.Gyn. News)
Source: Ob.Gyn. News - September 30, 2009 Category: OBGYN Authors: JOYCE FRIEDEN Tags: Clinical Rounds Source Type: journals

Diabetes Drug Could Cause Pancreatic CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(NaturalNews) The popular diabetes drug sitagliptin (marketed as Januvia) may increase the risk of pancreatic cancer, according to study conducted by researchers from the University of California-Los Angeles and published in the journal Diabetes."Type 2 diabetes is a lifelong disease -- people often take the same drugs for many years, so any adverse effect that could over time increase the risk for pancreatic cancer would be a concern," said lead researcher Peter Butler. "A concern here is that the unwanted effects of this drug on the pancreas would likely not be detected in humans unless the pancreas was removed and exami...
Source: NaturalNews.com - September 28, 2009 Category: Consumer Health Advice Source Type: news

Alkermes Announces Amylin and Lilly Will Present More than 20 Studies for Exenatide at EASD 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN DIEGO & INDIANAPOLIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 24, 2009 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 24, 2009 Category: Pharmaceuticals Source Type: clinical trials

Versartis Presents Preclinical Data For Novel Type 2 Diabetes DrugEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Versartis, Inc. today presented preclinical data demonstrating the potential for monthly dosing of its lead product, VRS-859 (exenatide-XTEN), for the treatment of type 2 diabetes. The data were presented by Jeffrey Cleland, Ph.D., Founder and Chief Executive Officer of Versartis, at the IBC Protein Engineering & Design Conference in San Diego. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 24, 2009 Category: Consumer Health News Tags: Diabetes Source Type: news

New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The proglucagon gene (gcg) encodes both glucagon and glucagon-like pepetide-1 (GLP-1), produced in pancreatic alpha cells and intestinal endocrine L cells, respectively. The incretin hormone GLP-1 stimulates insulin secretion and pro-insulin gene transcription. GLP-1 also enhances pancreatic beta-cell proliferation, inhibits cell apoptosis, and has been utilized in the trans-differentiation of insulin producing cells. A long-term effective GLP-1 receptor agonist, Byetta, has now been developed as the drug in treating type II diabetes and potentially other metabolic disorders. The expression of gcg and the production of...
Source: Cellular Signalling - September 18, 2009 Category: Cytology Authors: Yu Z, Jin T Tags: Cell Signal Source Type: journals

Intarcia Therapeutics, Inc. Commences Enrollment Of ITCA 650 Phase 2 Study In Type 2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Intarcia Therapeutics, Inc. announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily injection form of exenatide. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 18, 2009 Category: Consumer Health News Tags: Diabetes Source Type: news